Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Corinne Goldsmith Dickinson Center for Multiple Sclerosis Stories

2012-01-19 05:30:00

ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today the initiation of the Phase II clinical trial of Trimesta(TM)( )(oral estriol) for the treatment of cognitive dysfunction in multiple sclerosis (MS). This clinical trial is intended to enroll 64 relapsing-remitting or secondary-progressive female MS patients at University...

2012-01-11 06:35:56

(Ivanhoe Newswire)-- Recent studies give hope for patients with the irreversible disease known as MS or multiple sclerosis by possibly reversing the aging effects of the central nervous system. Approximately 100,000 people in the United Kingdom, 400,000 in the United States and several million worldwide are affected by MS. With age our bodies' regenerative abilities decrease. While wrinkles allow us to see visible aging effects of skin many other body tissues are left invisibly aging....

2012-01-06 15:13:06

Proof of principle study suggests the age-associated decline of the remyelination process is reversible New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell. As we get older, our bodies' ability to regenerate decreases. This is not only true for our skin (which is evident in the wrinkles that develop as we age) but also true for other tissues...

2011-11-21 13:16:00

Landmark Study Targets Repair and Regeneration for MS Patients NEW YORK, Nov. 21, 2011 /PRNewswire-USNewswire/ -- The Multiple Sclerosis Research Center of New York (MSRCNY) and the International Cellular Medicine Society (ICMS) jointly announced today the ICMS Institutional Review Board's (IRB) approval of the first study to use autologous brain-like or neural stem cells for multiple sclerosis. "We are entering a whole new world of possibilities for our patients" said Dr. Saud A....

2011-11-11 08:00:00

ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced that the Company's drug candidate, Trimesta(TM) (oral estriol), will be utilized in a new Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction observed in female multiple sclerosis (MS) patients. The Skirball Foundation and Adeona have pledged to equally support this...

New Drug Shows Promise Against Multiple Sclerosis
2011-11-02 04:45:28

An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men. The study, carried out by researchers at UCSF Medical Center, and involving hospitals in the United States, Canada, and Europe, is described this week in the British...

2011-07-20 06:00:00

ST. LOUIS, July 20, 2011 /PRNewswire/ -- Beginning July 29, Mark J. Tullman, MD, board-certified neurologist specializing in the diagnosis and treatment of multiple sclerosis (MS), will join The MS Center for Innovations in Care at Missouri Baptist Medical Center to help patients living with the chronic, often disabling affects of MS. The Center at Missouri Baptist is designated as a National Multiple Sclerosis Society Affiliated Center for Comprehensive Care. "I am extremely pleased to...

2011-04-14 15:27:12

Researchers from Mount Sinai School of Medicine will present several key studies at the American Academy of Neurology (AAN) annual meeting, including research providing critical insight into the prognosis and clinical treatment course of people with a certain subtype of Multiple Sclerosis (MS). The meeting is taking place April 9-16 in Honolulu. In a study titled "Evaluation of Progressive Relapsing MS Patients in the PROMISE Trial," Fred Lublin, MD, Saunders Family Professor of Neurology and...

2010-10-15 02:15:00

PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate...

2010-09-22 00:30:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis - the most common forms of the disease. The FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. To view the multimedia assets associated with this release,...